When it comes to biosimilar development, companies must thoroughly characterize both the originator and the new candidate to demonstrate biosimilarity. Fortunately, in-depth analysis is easier than ever before… The biopharma industry demands consistent quality and batch-to-batch comparability, which means that the in-depth characterization of a protein therapeutic and any modifications, such as glycosylation, is essential. The Christian Doppler Laboratory for Biosimilar Characterization, located at the University of Salzburg in Austria, has set out to address the challenges presented by protein analysis by seeking to develop and validate new techniques for characterizing therapeutic proteins. And to help with the mission, the laboratory looked to the expertise found at Thermo Fisher Scientific.
“I am an analytical chemist by training and have been involved in method development for biochromatography and biological mass spectrometry for almost 25 years.”
Christian Huber, Professor of Chemistry for Biosciences at the University of Salzburg
“I am a biotechnologist by training and developed a strong interest in glycobiology and glycan analysis during my studies at BOKU Vienna and ETH Zurich.”
Therese Wohlschlager, Postdoctoral Fellow in the Christian Doppler Laboratory for Biosimilar Characterization
“I’ve been attending all courses offered by Christian Huber's group including bioanalytics and structural biology or systems biology, and they were able to pique my curiosity for bioanalytics –especially for chromatography and mass spectrometry.”
Julia Tevini, Master Student in the Christian Doppler Laboratory for Biosimilar Characterization
“My professional experience, which I can use in my role as Scientific Advisor in Thermo Fisher Scientific, stems both from academia and the scientific instruments industry.”
Frank Steiner, Scientific Advisor at Thermo Fisher Scientific
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
